KellySBChailaEKinsellaK, et al. Using atypical symptoms and red flags to identify non-demyelinating disease. J Neurol Neurosurg Psychiatry2012; 83(1): 44–48.
2.
OntanedaDTallantyreEKalincikT, et al. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol2019; 18(10): 973–980.
3.
KaiseyMSolomonAJLuuM, et al. Incidence of multiple sclerosis misdiagnosis in referrals to two academic centers. Mult Scler Relat Disord2019; 30: 51–56.
4.
TanILVan SchijndelRAPouwelsPJ, et al. MR venography of multiple sclerosis. Am J Neuroradiol2000; 21(6): 1039–1042.
5.
SinneckerTClarkeMAMeierD, et al. Evaluation of the central vein sign as a diagnostic imaging biomarker in multiple sclerosis. JAMA Neurol2019; 76: 1446–1456.
6.
ClarkeMASamaraweeraAPFalahY, et al. Single Test to ARrive at Multiple Sclerosis (STAR-MS) diagnosis: A prospective pilot study assessing the accuracy of the central vein sign in predicting multiple sclerosis in cases of diagnostic uncertainty. Mult Scler 2019; 2019: 1352458519882282.
7.
MaggiPAbsintaMSatiP, et al. The ‘central vein sign’ in patients with diagnostic ‘red flags’ for multiple sclerosis: A prospective multicenter 3T study. Mult Scler2019; 2019: 1352458519876031.
8.
SamaraweeraAPFalahYPitiotA, et al. The MRI central vein marker; differentiating PPMS from RRMS and ischemic SVD. Neurol Neuroimmunol Neuroinflamm2018; 5(6): e496.
9.
SatiPOhJConstableRT, et al. The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: A consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nat Rev Neurol2016; 12(12): 714–722.
10.
FilippiMRoccaMACiccarelliO, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol2016; 15(3): 292–303.
